HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1-cyclopropylisoguanosine

an adenosine A1 agonist

Also Known As:

BN 063; BN-063; Adenosine, 1-cyclopropyl-1,2-dihydro-2-oxo-

Networked: 3 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Guanosine: 1156
        1-cyclopropylisoguanosine: 3
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Guanosine: 1156
      - 1-cyclopropylisoguanosine: 3
  - Ribonucleosides: 49
    - Guanosine: 1156
      - 1-cyclopropylisoguanosine: 3

Related Diseases

1.	Infarction (Infarctions) 06/12/1995 - "A significant reduction in infarct size, as a percentage of the area at risk, was noted with all three BN-063 treatment groups (control: 63.5 +/- 4.0%, I0.5-R0.5: 39.6 +/- 3.7%, R-0.5: 37.5 +/- 3.5%, R-1.0: 38.1 +/- 5.2%). " 06/12/1995 - "The results of this study demonstrate that BN-063, through activation of adenosine A1 receptors, exerts antiarrhythmic and anti-infarct effects during myocardial ischemia-reperfusion. "
2.	Ventricular Tachycardia 08/01/1994 - "Pretreatment with BN-063 (0.25, 0.5 and 1.0 mg kg-1) 10 min prior to occlusion significantly delayed the onset of ventricular arrhythmias, reduced the total number of ventricular premature contraction (VPC) and ventricular tachycardia (VT), decreased the incidence of VT and ventricular fibrillation (VF) and mortality during the first 30 min following left coronary artery ligation. "
3.	Myocardial Reperfusion Injury 06/12/1995 - "To assess the efficacy of the newly synthesized selective adenosine A1 receptor agonist, BN-063 (1-cyclopropylisoguanosine), against myocardial reperfusion injury, 31 rats underwent 45 min of left coronary artery occlusion and 1 h of reperfusion. " 06/12/1995 - "BN-063, a newly synthesized adenosine A1 receptor agonist, attenuates myocardial reperfusion injury in rats."
4.	Ventricular Fibrillation 08/01/1994 - "Pretreatment with BN-063 (0.25, 0.5 and 1.0 mg kg-1) 10 min prior to occlusion significantly delayed the onset of ventricular arrhythmias, reduced the total number of ventricular premature contraction (VPC) and ventricular tachycardia (VT), decreased the incidence of VT and ventricular fibrillation (VF) and mortality during the first 30 min following left coronary artery ligation. "
5.	Myocardial Ischemia (Ischemic Heart Diseases) 06/12/1995 - "The results of this study demonstrate that BN-063, through activation of adenosine A1 receptors, exerts antiarrhythmic and anti-infarct effects during myocardial ischemia-reperfusion. "

Related Drugs and Biologics

1.	Adenosine A1 Receptor

Related Therapies and Procedures

1.	Ligation